other
confidence high
sentiment neutral
materiality 0.50
Keros Therapeutics amends bylaws to update director nomination procedures, universal proxy rules
Keros Therapeutics, Inc.
- Updated advance notice provisions for director nominations, including requirements under Rule 14a-19 and limiting nominees to board seats available.
- Enhanced disclosure requirements for nominating stockholders and nominees, with obligation to update and supplement information.
- Clarified procedures for stockholder meetings, including meeting place, adjournment, notices, conduct, and stockholder lists.
- Conforming edits and other clarifying updates to improve consistency across bylaws.